Abstract
Cancers of the reproductive organs have a strong association with mitochondrial defects, and a deeper understanding of the role of this organelle in preneoplastic–neoplastic changes is important to determine the appropriate therapeutic intervention. Mitochondria are involved in events during cancer development, including metabolic and oxidative status, acquisition of metastatic potential, resistance to chemotherapy, apoptosis, and others. Because of their origin from melatonin-producing bacteria, mitochondria are speculated to produce melatonin and its derivatives at high levels; in addition, exogenously administered melatonin accumulates in the mitochondria against a concentration gradient. Melatonin is transported into tumor cell by GLUT/SLC2A and/or by the PEPT1/2 transporters, and plays beneficial roles in mitochondrial homeostasis, such as influencing oxidative phosphorylation and electron flux, ATP synthesis, bioenergetics, calcium influx, and mitochondrial permeability transition pore. Moreover, melatonin promotes mitochondrial homeostasis by regulating nuclear DNA and mtDNA transcriptional activities. This review focuses on the main functions of melatonin on mitochondrial processes, and reviews from a mechanistic standpoint, how mitochondrial crosstalk evolved in ovarian, endometrial, cervical, breast, and prostate cancers relative to melatonin’s known actions. We put emphasis on signaling pathways whereby melatonin interferes within cancer-cell mitochondria after its administration. Depending on subtype and intratumor metabolic heterogeneity, melatonin seems to be helpful in promoting apoptosis, anti-proliferation, pro-oxidation, metabolic shifting, inhibiting neovasculogenesis and controlling inflammation, and restoration of chemosensitivity. This results in attenuation of development, progression, and metastatic potential of reproductive cancers, in addition to lowering the risk of recurrence and improving the life quality of patients.
Similar content being viewed by others
References
Weiderpass E, Labrèche F (2012) Malignant tumors of the female reproductive system. Saf Health Work 3:166–180
Chuffa LG, Lupi-Júnior LA, Costa AB, Amorim JP, Seiva FR (2017) The role of sex hormones and steroid receptors on female reproductive cancers. Steroids 118:93–108
Stangelberger A, Waldert M, Djavan B (2008) Prostate cancer in elderly men. Rev Urol 10:111–119
Kong B, Tsuyoshi H, Orisaka M, Shieh DB, Yoshida Y, Tsang BK (2015) Mitochondrial dynamics regulating chemoresistance in gynecological cancers. Ann N Y Acad Sci 1350:1–16
Dan HC, Sun M, Kaneko S et al (2004) Akt phosphorylation and stabilization of x linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279:5405–5412
Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK (2008) CDDP induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 68:4511–4517
Woo MG, Xue K, Liu JY, McBride H, Tsang BK (2012) Calpain-mediated processing of p53 associated, Parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking. J Biol Chem 287:3963–3975
Lissoni P, Rovelli F, Meregalli S et al (1997) Melatonin as a new possible anti-inflammatory agent. J Biol Regul Homeost Agents 11:157–159
Vijayalaxmi Thomas CR Jr, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575–2601
Seely D, Wu P, Fritz H et al (2012) Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther 11:293–303
Wang YM, Jin BZ, Ai F et al (2012) The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 169:1213–1220
Del Fabbro E, Dev R, Hui D, Palmer L et al (2013) Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 31:1271–1276
Sookprasert A, Johns NP, Phunmanee A et al (2014) Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial. Anticancer Res 34:7327–7337
Ben-David MA, Elkayam R, Gelernter I et al (2016) Melatonin for prevention of breast radiation dermatitis: a phase II, prospective, double-blind randomized trial. Isr Med Assoc J 18:188–192
Onseng K, Johns NP, Khuayjarernpanishk T et al (2017) Beneficial effects of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J Altern Complement Med 12:957–963
Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B (2017) Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideas. Cell Mol Life Sci 74:3863–3881
Proietti S, Cucina A, Minini M, Bizzarri M (2017) Melatonin, mitochondria, and the cancer cell. Cell Mol Life Sci 74:4015–4025
Cedikova M, Kripnerova M, Dvorakova J et al (2016) Mitochondria in white, brown, and beige adipocytes. Stem Cells Int 2016:6067349
Tan DX, Manchester LC, Qin L, Reiter RJ (2016) Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. Int J Mol Sci 17:E2124
TeSlaa T, Setoguchi K, Teitell MA (2016) Mitochondria in human pluripotent stem cell apoptosis. Semin Cell Dev Biol 52:76–83
Chandel NS (2014) Mitochondria as signaling organelles. BMC Biol 12:34
Kaelin WG Jr, McKnight SL (2013) Influence of metabolism on epigenetics and disease. Cell 153:56–69
Lenaz G, Genova ML (2010) Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. Antioxid Redox Signal 12:961–1008
Ahmed KA, Sawa T, Ihara H, Shigemoto F, Hozumi M, Takaaki A (2012) Regulation by mitochondrial superoxide and NADPH oxidase of cellular formation of nitrated cyclic GMP: potential implications for ROS signalling. Biochem J 441:719–730
Obata T (2002) Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping. Toxicol Lett 132:83–93
Lipinski B (2011) Hydroxyl radical and its scavengers in health and disease. Oxid Med Cell Longev 2011:809696
Baharvand-Ahmadi B, Bahmani M, Tajeddini P, Nasrollah N, Mahmoud RK (2016) An ethno-medicinal study of medicinal plants used for the treatment of diabetes. J Nephropathol 5:44–50
Sadeghi M, Khosravi-Boroujeni H, Sarrafzadegan N et al (2014) Cheese consumption in relation to cardiovascular risk factors among Iranian adults-IHHP study. Nutr Res Pract 8:336–341
Sharafati-Chaleshtori R, Shirzad H, Rafieian-Kopaei M, Soltani A (2017) Melatonin and human mitochondrial diseases. J Res Med Sci 22:2
Penta JS, Johnson FM, Wachsman JT, Copeland WC (2001) Mitochondrial DNA in human malignancy. Mutat Res 488:119–133
Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7:65–74
Yang Y, Karakhanova S, Hartwig W, D’Haese JG, Philippov PP, Werner J, Bazhin AV (2016) Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J Cell Physiol 231:2570–2581
Suzuki S, Naito A, Asano T, Teresa TE, Shrikanth AG, Masahiro H (2008) Constitutive activation of AKT pathway inhibits TNF-induced apoptosis in mitochondrial DNA-deficient human myelogenous leukemia ML-1a. Cancer Lett 268:31–37
Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4:552–565
Yu J, Nagasu H, Murakami T, Hoang H, Broderick L, Hoffman HM, Horng T (2014) Inflammasome activation leads to caspase-1 dependent mitochondrial damage and block of mitophagy. Proc Natl Acad Sci USA 111:15514–15519
Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9:447–464
Zhang E, Zhang C, Su Y, Cheng T, Shi C (2011) Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov Today 16:140–146
Chen X, Qian Y, Wu S (2015) The Warburg effect: evolving interpretations of an established concept. Free Radic Biol Med 79:253–263
Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434
Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297–308
Jose C, Bellance N, Rossignol R (2011) Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma? Biochim Biophys Acta 1807:552–561
Smolkova K, Bellance N, Scandurra F et al (2010) Mitochondrial bioenergetic adaptations of breast cancer cells to a glycemia and hypoxia. J Bioenerg Biomembr 42:55–67
Goto M, Miwa H, Suganuma K et al (2014) Adaptation of leukemia cells to hypoxic condition through switching the energy metabolism or avoiding the oxidative stress. BMC Cancer 14:76
Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Ježek P (2011) Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 43:950–968
Carew JS, Huang P (2002) Mitochondrial defects in cancer. Mol Cancer 1:9
Ju YS, Alexandrov LB, Gerstung M et al (2014) Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife 1:3
Zong WX, Rabinowitz JD, White E (2016) Mitochondria and cancer. Mol Cell 61:667–676
Tan DJ, Bai RK, Wong LJ (2002) Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 62:972–976
Sharp MG, Adams SM, Walker RA, Brammar WJ, Varley JM (1992) Differential expression of the mitochondrial gene cytochrome oxidase II in benign and malignant breast tissue. J Pathol 168:163–168
Liu VW, Shi HH, Cheung AN et al (2001) High incidence of somatic mitochondrial DNAmutations in human ovarian carcinomas. Cancer Res 61:5998–6001
Feng D, Xu H, Li X et al (2016) An association analysis between mitochondrial DNA content, G10398A polymorphism, HPV infection, and the prognosis of cervical cancer in the chinese han population. Tumour Biol 37:5599–5607
Zhai K, Chang L, Zhang Q et al (2011) Mitochondrial C150T polymorphism increases the risk of cervical cancer and HPV infection. Mitochondrion 4:559–563
Guardado-Estrada M, Medina-Martínez I, Juárez-Torres E et al (2012) The amerindian mtDNA haplogroup B2 enhances the risk of HPV for cervical cancer: de-regulation of mitochondrial genes may be involved. J Hum Genet 57:269–276
Liu VW, Yang HJ, Wang Y et al (2003) High frequency of mitochondrial genome instability in human endometrial carcinomas. Br J Cancer 89:697–701
Wang Y, Liu VW, Tsang PC, Chui PM, Cheung ANY, Khoo US, Nagley P (2006) Microsatellite instability in mitochondrial genome of common female cancers. Int J Gynecol Cancer 1:259–266
Semczuk A, Lorenc A, Putowski L, Bartnik E (2006) Clinic prognostical features of endometrial cancer patients with somatic mtDNA mutations. Oncol Rep 16:1041–1045
Kalsbeek AMF, Chan EKF, Grogan J et al (2018) Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. Prostate 78:25–31
Kalsbeek AMF, Chan EKF, Corcoran NM, Hovens CM, Hayes VM (2017) Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management. Oncotarget 8:71342–71357
Creed J, Klotz L, Harbottle A, Maggrah A, Reguly B, George A, Gnanapragasm V (2018) A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA ‘grey zone’. World J Urol 36:341–348
Feng YM, Jia YF, Su LY, Wang D, Lv L, Xu L, Yao YG (2013) Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin. Autophagy 9:1395–1406
Peng TI, Hsiao CW, Reiter RJ, Tanaka M, Lai YK, Jou MJ (2012) mtDNA T8993G mutation-induced mitochondrial complex V inhibition augments cardiolipin-dependent alterations in mitochondrial dynamics during oxidative, Ca(2+), and lipid insults in NARP cybrids: a potential therapeutic target for melatonin. J Pineal Res 52:93–106
Scott AE, Cosma GN, Frank AA, Wells RL, Gardner HS (2001) Disruption of mitochondrial respiration by melatonin in MCF-7 cells. Toxicol Appl Pharmacol 171:149–156
Gilad E, Cuzzocrea S, Zingarelli B, Salzman AL, Szabó C (1997) Melatonin is a scavenger of peroxynitrite. Life Sci 60:169–174
Mansouri A, Gaou I, De Kerguenec C et al (1999) An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 117:181–190
Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B (2001) Acute ethanol administration oxidatively damages and depletes mitochondrial dna in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther 298:737–743
Lerner AB, Case JD, Takahashy Y et al (1960) Structure of melatonin and 5 methoxy-indole 3-acetic acid from bovine pineal gland. J Biol Chem 235:1992–1997
Champney TH, Holtorf AP, Steger RW, Reiter RJ (1984) Concurrent determination of enzymatic activities and substrate concentrations in the melatonin synthetic pathway within the same rat pineal gland. J Neurosci Res 11:59–66
Acuña-Castroviejo D, Rahim I, Acuña-Fernández C et al (2017) Melatonin, clockgenes and mitochondria in sepsis. Cell Mol Life Sci 74:3965–3987
Jockers R, Delagrange P, Dubocovich ML et al (2016) Update on melatonin receptors: IUPHAR review. Br J Pharmacol 173:2702–2725
Becker-Andre M, Wiesenberg I, Schaeren-Wiemers N, André E, Missbach M, Saurat JH, Carlberg C (1994) Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 269:28531–28534
Chuffa LG, Seiva FR, Fávaro WJ et al (2011) Melatonin reduces LH, 17 beta-estradiol and induces differential regulation of sex steroid receptors in reproductive tissues during rat ovulation. Reprod Biol Endocrinol 9:108
Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT (2012) Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 351:152–166
Chuffa LG, Seiva FR, Fávaro WJ et al (2013) Melatonin and ethanol intake exert opposite effects on circulating estradiol and progesterone and differentially regulate sex steroid receptors in the ovaries, oviducts, and uteri of adult rats. Reprod Toxicol 39:40–49
Tamura H, Takasaki A, Taketani T et al (2014) Melatonin and female reproduction. J Obstet Gynaecol Res 40:1–11
Reiter RJ, Tan DX, Manchester LC et al (2009) Melatonin and reproduction revisited. Biol Reprod 81:445–456
Tamura H, Takasaki A, Miwa I et al (2008) Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res 44:280–287
Tamura H, Kawamoto M, Sato S et al (2017) Long-term melatonin treatment delays ovarian aging. J Pineal Res 62:e12381
Song C, Peng W, Yin S et al (2016) Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice. Sci Rep 6:35165
Ferreira CS, Carvalho KC, Maganhin CC et al (2016) Does melatonin influence the apoptosis in rat uterus of animals exposed to continuous light? Apoptosis 21:155–162
Gobbo MG, Costa CF, Silva DG, de Almeida EA, Góes RM (2015) Effect of melatonin intake on oxidative stress biomarkers in male reproductive organs of rats under experimental diabetes. Oxid Med Cell Longev 2015:614579
Martín M, Macias M, Escames G, León J, Acuña-Castroviejo D (2000) Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 14:1677–1679
Venegas C, García JA, Escames G et al (2012) Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 52:217–227
Acuña-Castroviejo D, Escames G, Venegas C et al (2014) Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 71:2997–3025
He C, Wang J, Zhang Z et al (2016) Mitochondria synthesize melatonin to ameliorate its function and improve mice oocyte’s quality under in vitro conditions. Int J Mol Sci 17:E939
Suofu Y, Li W, Jean-Alphonse FG et al (2017) Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proc Natl Acad Sci USA 114:7997–8006
Semak I, Naumova M, Korik E, Terekhovich V, Wortsman J, Slominski A (2005) A novel metabolic pathway of melatonin: oxidation by cytochrome c. Biochemistry 44:9300–9307
Martín M, Macías M, León J, Escames G, Khaldy H, Acuña-Castroviejo D (2002) Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 34:348–357
Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ (2004) Melatonin and mitochondrial function. Life Sci 75:765–790
López A, García JA, Escames G, Venegas C, Ortiz F, López LC, Acuña-Castroviejo D (2009) Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 46:188–198
Acuña-Castroviejo D, Lopez LC, Escames G, López A, García JA, Reiter RJ (2011) Melatonin-mitochondria interplay in health and disease. Curr Top Med Chem 11:221–240
Acuña-Castroviejo D, Escames G, Carazo A, Reiter RJ (2002) Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr Top Med Chem 2:133–151
Jou MJ, Peng TI, Yu PZ et al (2007) Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 43:389–403
Bonnefont-Rousselot D (2014) Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. Endocr Metab Immune Disord Drug Targets 14:159–168
Galano A, Tan DX, Reiter RJ (2018) Melatonin: a versatile protector against oxidative DNA damage. Molecules 23:E530
Galano A, Reiter RJ (2018) Melatonin and its metabolites vs oxidative stress: from individual actions to collective protection. J Pineal Res 65:e12514
Munoz-Casares FC, Padillo FJ, Briceno J et al (2006) Melatonin reduces apoptosis and necrosis induced by ischemia/reperfusion injury of the pancreas. J Pineal Res 40:195–203
Paradies G, Petrosillo G, Paradies V, Reiter RJ, Ruggiero FM (2010) Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 48:297–310
Mayo JC, Sainz RM, Gonzalez MP, Cepas V, Tan DX, Reiter RJ (2017) Melatonin and sirtuins: a “not-so unexpected” relationship. J Pineal Res 62:e12391
Horbay R, Bilyy R (2016) Mitochondrial dynamics during cell cycling. Apoptosis 21:1327–1335
Hardeland R, Madrid JA, Tan DX, Reiter RJ (2012) Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 52:139–166
Swietoslawski J, Karasek M (1993) Day-night changes in the ultrastructure of pinealocytes in the Syrian hamster: a quantitative study. Endokrynol Pol 44:81–87
Pei H, Du J, Song X et al (2016) Melatonin prevents adverse myocardial infarction remodeling via Notch1/Mfn2 pathway. Free Radic Biol Med 97:408–417
Randow F, Youle RJ (2014) Self and nonself: how autophagy targets mitochondria and bacteria. Cell Host Microbe 15:403–411
Kang JW, Hong JM, Lee SM (2016) Melatonin enhances mitophagy and mitochondrial biogenesis in rats with carbon tetrachloride-induced liver fibrosis. J Pineal Res 60:383–393
Lin C, Chao H, Li Z et al (2016) Melatonin attenuates traumatic brain injury-induced inflammation: a possible role for mitophagy. J Pineal Res 61:177–186
Jou MJ (2011) Melatonin preserves the transient mitochondrial permeability transition for protection during mitochondrial Ca2+ stress in astrocyte. J Pineal Res 50:427–435
Akhmedov AT, Rybin V, Marin-Garcia J (2015) Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart. Heart Fail Rev 20:227–249
Vitale SG, Rossetti P, Corrado F et al (2016) How to achieve high-quality oocytes? The key role of Myo-Inositol and melatonin. Int J Endocrinol 2016:4987436
Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ (2011) Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 12:167–188
Jimenez-Aranda A, Fernandez-Vazquez G, Campos D et al (2013) Melatonin induces browning of inguinal white adipose tissue in zucker diabetic fatty rats. J Pineal Res 55:416–423
Reiter RJ, Tan DX, Rosales-Corral S, Bing X (2018) Mitochondria: central organelles for melatonin’s antioxidant and anti-aging actions. Molecules 23:509
Muller FL, Liu Y, Van Rammen H (2004) Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 279:49064–49073
Martín M, Macías M, Escames G, Reiter RJ, Agapito MT, Ortiz GG, Acuña-Castroviejo D (2000) Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 28:242–248
Reyes-Toso CF, Ricci CR, de Mignone IR et al (2003) In vitro effect of melatonin on oxygen consumption in liver mitochondria of rats. Neuro Endocrinol Lett 24:341–344
Pacini N, Borziani F (2016) Oncostatic-cytoprotective effect of melatonin and other bioactive molecules: a common target in mitochondrial respiration. Int J Mol Sci 17:341
Zhang H, Zhang HM, Wu LP et al (2011) Impaired mitochondrial complex III and melatonin responsive reactive oxygen species generation in kidney mitochondria of db/db mice. J Pineal Res 51:338–344
Fu JL, Zhang HM, Zhang H, Kamat A, Yeh CK, Zhang BX (2013) A melatonin-based fluorescence method for the measurement of mitochondrial complex III function in intact cells. J Pineal Res 55:364–370
Bizzarri M, Proietti S, Cucina A, Reiter RJ (2013) Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 17:1483–1496
Sánchez-Hidalgo M, Guerrero JM, Villegas I, Packham G, de la Lastra CA (2012) Melatonin, a natural programmed cell death inducer in cancer. Curr Med Chem 19:3805–3821
Yun J, Mullarky E, Lu C et al (2015) Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350:1391–1396
Oyewole AO, Birch-Machin MA (2015) Mitochondria-targeted antioxidants. FASEB J 29:4766–4771
Lowes DA, Webster NR, Murphy MP, Galleyet HF (2013) Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth 110:472–480
Hevia D, Gonzalez-Menendez P, Quiros-Gonzalez I et al (2015) Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res 58:234–250
Huo X, Wang C, Yu Z et al (2017) Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: an implication of the therapeutic potential. J Pineal Res 62:e12390
Chuffa LG, Alves MS, Martinez M et al (2016) Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma. Endocr Relat Cancer 23:65–76
Prat J (2012) Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 60:237–249
Karaca B, Atmaca H, Bozkurt E et al (2013) Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol Biol Rep 40:3925–3933
Togashi K, Okada M, Yamamoto M et al (2018) A small-molecule kinase inhibitor, CEP-1347, inhibits survivin expression and sensitizes ovarian cancer stem cells to paclitaxel. Anticancer Res 38:4535–4542
Ornelas A, McCullough CR, Lu Z et al (2016) Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16:824
Xie Q, Su J, Jiao B et al (2016) ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. Int J Oncol 49:2507–2519
Matsuura K, Huang NJ, Cocce K, Zhang L, Kornbluth S (2017) Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin. Oncogene 36:1698–1706
Yang J, Zhao X, Tang M et al (2017) The role of ROS and subsequent DNA-damage response in PUMA-induced apoptosis of ovarian cancer cells. Oncotarget 8:23492–23506
Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E (1999) The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 26:129–136
Vervliet T, Clerix E, Seitaj B, Ivanova H, Monaco G, Bultynck G (2017) Modulation of Ca(2+) signaling by anti-apoptotic B-Cell lymphoma 2 proteins at the endoplasmic reticulum-mitochondrial interface. Front Oncol 7:75
Akl H, Bultynck G (2013) Altered Ca2+ signaling in cancer cells: proto-oncogenes and tumor suppressors targeting IP3 receptors. Biochim Biophys Acta 1835:180–193
Giorgi C, Missiroli S, Patergnani S, Duszynski J, Wieckowski MR, Pinton P (2015) Mitochondria-associated membranes: composition, molecular mechanisms, and physiopathological implications. Antioxid Redox Signal 22:995–1019
Hwang MS, Schwall CT, Pazarentzos E, Datler C, Alder NN, Grimm S (2014) Mitochondrial Ca2+ influx targets cardiolipin to disintegrate respiratory chain complex II for cell death induction. Cell Death Differ 21:1733–1745
Eckenrode EF, Yang J, Velmurugan GV, Foskett JK, White C (2010) Apoptosis protec-tion by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca2+ signaling. J Biol Chem 285:13678–13684
Monaco G, Beckers M, Ivanova H, Missiaen L, Parys JB, De Smedt H, Bultynck G (2012) Profiling of the Bcl-2/Bcl-XL-binding sites on type 1 IP3 receptor. Biochem Biophys Res Commun 428:31–35
Hanson CJ, Bootman MD, Distelhorst CW, Wojcikiewicz RJ, Roderick HL (2008) Bcl-2 suppresses Ca2+ release through inositol 1,4,5-trisphosphate receptors and inhibits Ca2+ uptake by mitochondria without affecting ER calcium store content. Cell Calcium 44:324–338
Xu L, Xie Q, Qi L et al (2018) Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Oncol Rep 39:985–992
Dai Y, Jin S, Li X, Wang D (2017) The involvement of Bcl-2 family proteins in AKT regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget 8:354–1368
Chuffa LG, Lupi Júnior LA, Seiva FR et al (2016) Quantitative proteomic profiling reveals that diverse metabolic pathways are influenced by melatonin in an in vivo model of ovarian carcinoma. J Proteome Res 15:3872–3882
Chovancova B, Hudecova S, Lencesova L et al (2017) Melatonin-induced changes in cytosolic calcium might be responsible for apoptosis induction in tumour cells. Cell Physiol Biochem 44:763–777
Kim JH, Jeong SJ, Kim B, Yun SM, Choi DY, Kim SH (2012) Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3cells. J Pineal Res 52:244–252
Collins A, Yuan L, Kiefer TL, Cheng Q, Lai L, Hill SM (2003) Overexpression of the mt1 melatonin receptor in mcf-7 human breast cancer cells inhibit mammary tumor formation in nude mice. Cancer Lett 189:49–57
Nakamura E, Kozaki K, Tsuda H et al (2008) Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 a (mtnr1a) in oral squamous-cell carcinoma. Cancer Sci 99:1390–1400
Jablonska K, Pula B, Zemla A et al (2014) Expression of the mt1 melatonin receptor in ovarian cancer cells. Int J Mol Sci 15:23074–23089
Zemła A, Grzegorek I, Dzięgiel P, Jabłońska K (2017) Melatonin synergizes the chemotherapeutic effect of cisplatin in ovarian cancer cells independently of MT1 melatonin receptors. Vivo 31:801–809
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7–30
Suarez AA, Felix AS, Cohn DE (2017) Bokhman Redux: endometrial cancer “types” in the 21st century. Gynecol Oncol 144:243–249
Silverberg SG, Kurman RJ, Nogales F et al (2003) Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumours: pathology and genetics—tumours of the breast and female genital organs, vol 217. IARC Press, Lyon, p 232123
Doghri R, Chaabouni S, Houcine Y et al (2018) Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors in endometrial cancer. Mol Clin Oncol 9:87–91
Matias-Guiu X, Davidson B (2014) Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch 464:315–331
Klinge CM (2017) Estrogens regulate life and death in mitochondria. J Bioenerg Biomembr 49:307–324
Cormio A, Cormio G, Musicco C, Sardanelli AM, Gasparre G, Gadaleta MN (2015) Mitochondrial changes in endometrial carcinoma: possible role in tumor diagnosis and prognosis (review). Oncol Rep 33:1011–1018
Musicco C, Cormio G, Pesce V et al (2018) Mitochondrial dysfunctions in type I endometrial carcinoma: exploring their role in oncogenesis and tumor progression. Int J Mol Sci 19:E2076
Wang Y, Liu VW, Xue WC, Tsang PC, Cheung AN, Ngan HY (2005) The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. Gynecol Oncol 98:104–110
Cormio A, Guerra F, Cormio G, Pesce V et al (2009) The PGC-1alpha–dependent pathway of mitochondrial biogenesis is upregulated in type I endometrial cancer. Biochem Biophys Res Commun 390:1182–1185
Guerra F, Kurelac I, Cormio A et al (2011) Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet 20:2394–2405
Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochemistry J417:1–13
Papa S, De Rasmo D, Technikova-Dobrova Z et al (2012) Respiratory chain complex I, a main regulatory target of the cAMP/PKA pathway is defective in different human diseases. FEBS Lett 586:568–577
Cinar B, Collak FK, Lopez D et al (2011) MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res 71:4303–4313
Zhao Q, Ye M, Yang W et al (2018) Effect of Mst1 on endometriosis apoptosis and migration: role of Drp1-related mitochondrial fission and parkin-required mitophagy. Cell Physiol Biochem 45:1172–1190
Attarha S, Andersson S, Mints M, Souchelnytskyi S (2014) Mammalian sterile-like1 kinase inhibits TGFβ and EGF-dependent regulation of invasiveness, migration and proliferation of HEC-1-endometrial cancer cells. Int J Oncol 45:853–860
Grin W, Grünberger W (1998) A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Investig 45:62–65
Witek A, Jęda A, Baliś M et al (2015) Expression of melatonin receptors genes and genes associated with regulation of their activity in endometrial cancer. Ginekol Pol 86:248–255
Osanai K, Kobayashi Y, Otsu M, Izawa T, Sakai K, Iwashita M (2017) Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells. Hum Cell 30:209–215
Watanabe M, Kobayashi Y, Takahashi N, Kiguchi K, Ishizuka B (2008) Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line. J Obstet Gynaecol Res 34:567–573
Kobayashi Y, Itoh MT, Kondo H et al (2003) Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res 35:71–74
Ciortea R, Costin N, Braicu I et al (2011) Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats. Anticancer Res 31:2637–2643
Bentivegna E, Gouy S, Maulard A, Chargari C, Leary A, Morice P (2016) Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol 17:240–253
Lai JC, Chou YJ, Huang N et al (2013) Survival analysis of stage IIA1 and IIA2 cervical cancer patients. Taiwan J Obstet Gynecol 52:33–38
Kuzuya K (2004) Chemoradiotherapy for uterine cancer: current status and perspectives. Int J Clin Oncol 9:458–470
Kakimoto PA, Kowaltowski AJ (2016) Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance. Redox Biol 8:216–225
Yan D, Zhu D, Zhao X, Su J (2018) SHP-2 restricts apoptosis induced by chemotherapeutic agents via Parkin-dependent autophagy in cervical cancer. Cancer Cell Int 18:8
Chen L, Liu L, Li Y, Gao J (2018) Melatonin increases human cervical cancer HeLa cells apoptosis induced by cisplatin via inhibition of JNK/Parkin/mitophagy axis. In Vitro Cell Dev Biol Anim 54:1–10
Pariente R, Pariente JA, Rodríguez AB, Espino J (2016) Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation. J Pineal Res 60:55–64
Pariente R, Bejarano I, Espino J, Rodríguez AB, Pariente JA (2017) Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics. Cancer Chemother Pharmacol 80:985–998
Galluzzi L, Vitale I, Michels J et al (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:1257
Karasek M, Kowalski AJ, Suzin J, Zylinska K, Swietoslawski J (2005) Serum melatonin circadian profiles in women suffering from cervical cancer. J Pineal Res 39:73–76
Anisimov VN, Zabezhinski MA, Popovich IG et al (2000) Inhibitory effect of melatonin on 7, 12-dimethylbenz[a]anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett 156:199–205
Chen LD, Leal BZ, Reiter RJ et al (1995) Melatonin’s inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione concentrations. Cancer Lett 91:153–159
Fourkala EO, Blyuss O, Field H et al (2016) Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: case control study in uk collaborative cancer trial of ovarian cancer screening (UKCTOCS). Steroids 110:62–69
Omoto Y, Iwase H (2015) Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci 106:337–343
Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G (2005) Breast cancer. Lancet 365:1727–1741
Collaborative Group on Hormonal Factors in Breast Cancer (2012) Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118.964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13:1141–1151
Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ (2010) Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 17:4462–4481
Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ (2012) Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs 21:819–831
Hill SM, Belancio VP, Dauchy RT et al (2015) Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 22:183–204
Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA (2009) Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 11:1–15
Hill SM, Blask DE, Xiang S et al (2011) Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia 16:235–245
Proietti S, Cucina A, Reiter R, Bizzarri M (2013) Molecular mechanisms of melatonin’s inhibitory actions on breast cancer. Cell Mol Life Sci 70:2139–2157
Gunter TE, Gunter KK, Sheu SS, Gavin CE (1994) Mitochondrial calcium transport: physiological and pathological relevance. Am J Physiol 267:313–339
Gunter TE, Buntinas L, Sparagna G, Eliseev R, Gunter K (2000) Mitochondrial calcium transport: mechanisms and functions. Cell Calcium 28:285–296
Concolino A, Olivo E, Tamme L et al (2018) Proteomics analysis to assess the role of mitochondria in brca1-mediated breast tumorigenesis. Proteomes 6:E16
Kim MY, Choi EO, Hwang Bo H et al (2018) Reactive oxygen species-dependent apoptosis induction by water extract of citrus unshiu peel in MDA-MB-231 human breast carcinoma cells. Nutr Res Pract 12:129–134
Oo PS, Yamaguchi Y, Sawaguchi A et al (2018) Estrogen regulates mitochondrial morphology through phosphorylation of dynamin-related protein 1 in mcf7 human breast cancer cells. Acta Histochem Cytochem 51:21–31
Vic P, Vignon F, Derocq D, Rochefort H (1982) Effect of estradiol on the ultrastructure of the MCF7 human breast cancer cells in culture. Cancer Res 42:667–673
Westermann B (2010) Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 11:872–884
Trotta AP, Chipuk JE (2017) Mitochondrial dynamics as regulators of cancer biology. Cell Mol Life Sci 74:1999–2017
Kashatus JA, Nascimento A, Myers LJ et al (2015) Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell 57:537–551
Zhao J, Zhang J, Yu M et al (2013) Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 32:4814–4824
Chuang JI, Pan IL, Hsieh CY et al (2016) Melatonin prevents the Drp1-dependent mitochondrial fission and oxidative insult in the cortical neurons after MPP treatment. J Pineal Res 61:230–240
Xu S, Pi H, Zhang L et al (2016) Melatonin prevents abnormal mitochondrial dynamics resulting from the neurotoxicity of cadmium by blocking calcium-dependent translocation of Drp1 to the mitochondria. J Pineal Res 60:291–302
Parameyong A, Charngkaew K, Govitrapong P et al (2013) Melatonin attenuates methamphetamine induced disturbances in mitochondrial dynamics and degeneration in neuroblastoma SH-SY5Y cells. J Pineal Res 55:313–323
Zhou TJ, Zhang SL, He CY et al (2017) Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1. Theranostics 7:1389–1406
Suwanjang W, Abramov AY, Charngkaew K, Govitrapong P, Chetsawang B (2016) Melatonin prevents cytosolic calcium overload, mitochondrial damage and cell death due to toxically high doses of dexamethasone-induced oxidative stress in human neuroblastoma SH-SY5Y cells. Neurochem Int 97:34–41
Prieto-Domínguez N, Ordóñez R, Fernández A et al (2016) Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res 61:396–407
Pedram A, Razandi M, Wallace DC, Levin ER (2006) Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 17:2125–2137
Moselhy SS, Al Mslmani MA (2008) Chemopreventive effect of lycopene alone or with melatonin against the genesis of oxidative stress and mammary tumors induced by 7,12 dimethyl(a)benzanthracene in Sprague–Dawley female rats. Mol Cell Biochem 319:175–180
Cucina A, Proietti S, D’Anselmi F, Coluccia P, Dinicola S, Frati L, Bizzarri M (2009) Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 46:172–180
Srinivasula SM, Ahmad M, Fernandes-Alnemri T et al (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1:949–957
Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW (1999) Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284:156–159
Moroni MC, Hickman ES, Lazzerini DE et al (2001) Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3:552–558
Riedl SJ (2005) Structure of the apoptotic protease-activating factor 1 bound to ADP. Nature 434:926–933
Wang J, Xiao X, Zhang Y et al (2012) Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 53:77–90
Sabzichi M, Samadi N, Mohammadian J, Hamishehkar H, Akbarzadeh M, Molavi O (2016) Sustained release of melatonin: a novel approach in elevating efficacy of tamoxifen in breast cancer treatment. Colloids Surf B Biointerfaces 145:64–71
Koşar PA, Nazıroğlu M, Övey İS, Çiğ B (2016) Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: involvement of TRPV1 channels. J Membr Biol 249:129–140
Mao L, Cheng Q, Guardiola-Lemaître B et al (2010) In vitro and in vivo antitumor activity of melatonin receptor agonists. J Pineal Res 49:210–221
Yun SM, Woo SH, St Oh et al (2016) Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells. Mol Cell Endocrinol 422:64–73
Nooshinfar E, Bashash D, Safaroghli-Azar A, Bayati S, Rezaei-Tavirani M, Ghaffari SH, Akbari ME (2016) Melatonin promotes ATO-induced apoptosis in MCF-7 cells: proposing novel therapeutic potential for breast cancer. Biomed Pharmacother 83:456–465
Woo SM, Min KJ, Kwon TK (2015) Melatonin-mediated Bim up-regulation and cyclooxygenase-2 (COX-2) down-regulation enhances tunicamycin-induced apoptosis in MDA-MB-231 cells. J Pineal Res 58:310–320
Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ (2007) Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7:519–530
Tajbakhsh A, Pasdar A, Rezaee M (2017) The current status and perspectives regarding the clinical implication of intracellular calcium in breast cancer. J Cell Physiol 233:5623–5641
Xu HT, Yuan XB, Guan CB, Duan S, Wu CP, Feng L (2004) Calcium signaling in chemorepellant Slit2-dependent regulation of neuronal migration. Proc Natl Acad Sci USA 12:4296–4301
Nita LI, Hershfinkel M, Sekler I (2015) Life after the birth of the mitochondrial Na+/Ca2+ exchanger, NCLX. Sci China Life Sci 58:59–65
Barnes DM, Millis RR, Gillett CE, Ryder K, Skilton D, Fentiman IS, Rubens RD (2004) The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients. Endocr Relat Cancer 11:85–96
Hoenderop JG, Nilius B, Bindels RJ (2005) Calcium absorption across epithelia. Physiol Ver 85:373–422
Watson CS, Alyea RA, Jeng YJ, Kochukov MY (2007) Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues. Mol Cell Endocrinol 274:1–7
Busselberg D, Florea AM (2017) Targeting Intracellular calcium signaling ([Ca(2+)]i) to overcome acquired multidrug resistance of cancer cells: a mini-overview. Cancers (Basel) 9:48
Cui C, Merritt R, Fu L, Zui P (2017) Targeting calcium signaling in cancer therapy. Acta Pharm Sin 7:3–17
Brookes PS (2004) Mitochondrial nitric oxide synthase. Mitochondrion 3:187–204
Csordas G, Golenar T, Seifert EL et al (2013) MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca(2)(+) uniporter. Cell Metab 7:976–987
Wallace DC (2012) Mitochondria and cancer. Nat Rev Cancer 12:685–698
Curry MC, Luk NA, Kenny PA, Roberts-Thomson SJ, Monteith GR (2012) Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. J Biol Chem 287:28598–28608
VanHouten J, Sullivan C, Bazinet C et al (2010) PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proc Natl Acad Sci USA 25:11405–11410
Herschkowitz JI, Simin K, Weigman VJ et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:76
Curry MC, Peters AA, Kenny PA, Roberts-Thomson SJ, Monteith GR (2013) Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 434:695–700
França EL, Honorio-França AC, Fernandes RT, Marins CM, Pereira CC, Varotti Fde P (2016) The effect of melatonin adsorbed to polyethylene glycol microspheres on the survival of MCF-7 cells. Neuro Immunomodulation 23:27–32
Reiter RJ, Tan DX, Osuna C, Gitto E (2000) Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci 7:444–458
Naziroglu M, Karaoğlu A, Aksoy AO (2004) Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 195:221–230
Uguz AC, Cig B, Espino J et al (2012) Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J Pineal Res 53:91–98
Sag CM, Wagner S, Maier LS (2013) Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes. Free Radic Biol Med 63:338–349
Bejarano I, Espino J, Barriga C, Reiter RJ, Pariente JA, Rodríguez AB (2011) Pro-oxidant effect of melatonin in tumour leucocytes: relation with its cytotoxic and pro-apoptotic effects. Basic Clin Pharmacol Toxicol 108:14–20
Squecco R, Tani A, Zecchi-Orlandini S, Formigli L, Francini F (2015) Melatonin affects voltage-dependent calcium and potassium currents in MCF-7 cell line cultured either in growth or differentiation medium. Eur J Pharmacol 758:40–52
Mahapatra S, Marcantoni A, Zuccotti A, Carabelli V, Carbone E (2012) Equal sensitivity of cav1.2 and cav1.3 channels to the opposing modulations of PKA and PKG in mouse chromaffin cells. J Physiol 590:5053–5073
Margheri M, Pacini N, Tani A et al (2012) Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. Eur J Pharmacol 681:34–43
Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530
Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270
Vaupel P, Mayer A, Höckel M (2004) Tumor hypoxia and malignant progression. Methods Enzymol 381:335–354
Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51–56
Locasale JW, Grassian AR, Melman T et al (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43:869–874
Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, Stephanopoulos G (2016) Metabolic requirements for cancer cell proliferation. Cancer Metab 4:16
Possemato R, Marks KM, Shaul YD et al (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476:346–350
Pollari S, Käkönen SM, Edgren H et al (2011) Enhanced serine production by bine metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 125:421–430
Goncalves Ndo N, Rodrigues RV, Jardim-Perassi BV, Moschetta MG, Lopes JR, Colombo J, Zuccari DA (2014) Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. Anticancer Agents Med Chem 14:1302–1311
Sohn EJ, Won G, Lee J, Lee S, Kim SH (2015) Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells. J Cancer 6:19–28
Blask DE, Dauchy RT, Dauchy EM et al (2014) Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the warburg effect, lipid signaling and tumor growth prevention. PLoS One 9:102776
Das R, Gregory PA, Hollier BG, Tilley WD, Selth LA (2014) Epithelial plasticity in prostate cancer: principles and clinical perspectives. Trends Mol Med 20:643–655
Glass AS, Cary KC (2013) Risk-based prostate cancer screening: who and how? Curr Urol Rep 14:192–198
Gathirua-Mwang WG, Zhang J (2014) Dietary factors and risk for advanced prostate cancer. Eur J Cancer Prev 23:96–109
American Cancer Society. (2017) Information and resources about cancer: breast, colon, lung, prostate, skin. https://www.cancer.org/about-us.html. Accessed 26 June 2018
Xiao J, Howard L, Wan J (2017) Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk. Oncotarget 8:94900–94909
Sainz RM, Mayo JC, Tan D, León J, Manchester L, Reiter RJ (2005) Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63:29–43
Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764
Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
Tai SY, Huang SP, Bao BY, Wu MT (2016) Melatonin-sulfate/cortisol ratio and the presence of prostate cancer: a case–control study. Sci Rep 6:29606
Marelli MM, Limonta P, Maggi R, Motta M, Moretti RM (2000) Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 45:238–344
Xi SC, Siu SW, Fong SW, Shiu SY (2001) Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 46:52–61
Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT (2003) Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 35:177–182
Xi SC, Tam PC, Brown GM, Pang SF, Shiu SY (2000) Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influxin the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res 29:172–183
Tam CW, Mo CW, Yao KM, Shiu SY (2007) Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res 42:191–202
Tam CW, Chan KW, Liu VW et al (2008) Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res 45:403–412
Shiu SY, Pang B, Tam CW, Yao KM (2010) Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of galpha(s) and galpha(q) proteins. J Pineal Res 49:301–311
Bazwinsky-Wutschke I, Bieseke L, Mühlbauer E, Peschke E (2014) Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. J Pineal Res 56:82–96
Lonergan PE, Tindall DJ (2011) Androgen receptor signaling in prostate cancer development and progression. J Carcinog 10:20
Lupowitz Z, Rimler A, Zisapel N (2001) Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin. Cell Mol Life Sci 58:2129–2135
Rimler A, Culig Z, Levy-Rimler G et al (2001) Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate 49:145–154
Tam CW, Shiu S (2011) Functional interplay between Melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. J Pineal Res 51:297–312
Joo SS, Yoo YM (2009) Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 47:8–14
Moretti RM, Marelli MM, Maggi R et al (2000) Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 7:347–351
Rodriguez-Garcia A, Hevia D, Mayo JC et al (2017) Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells. Redox Biol 12:634–647
Calastretti A, Gatti G, Lucini V, Dugnani S, Canti G, Scaglione F, Bevilacqua A (2018) Melatonin analogue antiproliferative and cytotoxic effects on human prostate cancer cells. Int J Mol Sci 18:19
Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27–47
Cutruzzolà F, Giardina G, Marani M et al (2017) Glucose metabolism in the progression of prostate cancer. Front Physiol 8:97
Schöder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34:274–292
Hevia D, Gonzalez-Menendez P, Fernandez-Fernandez M et al (2017) Melatonin decreases glucose metabolism in prostate cancer cells: a 13c stable isotope-resolved metabolomic study. Int J Mol Sci 26:18
John RP, Nampoothiri KM, Pandey A (2007) Fermentative production of lactic acid from biomass: an overview on process developments and future perspectives. Appl Microbiol Biotechnol 74:524–534
Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, Talesa V (2001) Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res 66:67–72
de Bari L, Moro L, Passarella S (2013) Prostate cancer cells metabolize d-lactate inside mitochondria via a d-lactate dehydrogenase which is more active and highly expressed than in normal cells. FEBS Lett 587:467–473
Sayed RKA, Fernández-Ortiz M, Diaz-Casado ME et al (2018) The protective effect of melatonin against age-associated sarcopenia-dependent tubular aggregates formation, lactate depletion and mitochondrial changes. J Gerontol A Biol Sci Med Sci 73:1330–1338
Dauchy RT, Hoffman AE, Wren-Dail MA et al (2015) Daytime blue light enhances the nighttime circadian melatonin inhibition of human prostate cancer growth. Comp Med 65:473–485
Rodriguez-Garcia A, Mayo JC, Hevia D, Quiros-Gonzalez I, Navarro M, Sainz RM (2013) Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. J Pineal Res 54:33–45
Gilmore TD (2006) Introduction to NF-κB: players, pathways, perspectives. Oncogene 25:6680–6684
Wei B, Liang J, Hu J et al (2017) TRAF2 is a valuable prognostic biomarker in patients with prostate cancer. Med Sci Monit 23:4192–4204
Aggarwal BB (2003) Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745–756
Muri J, Heer S, Matsushita M et al (2018) The thioredoxin-1 system is essential for fueling DNA synthesis during T-cell metabolic reprogramming and proliferation. Nat Commun 9:1851
Reiter RJ, Tan DX, Fuentes-Broto L (2010) Melatonin: a multitasking molecule. Prog Brain Res 181:127–151
Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF (2017) Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res 62:e12370
Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K (2017) Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci 18:843
Acknowledgements
We are grateful to Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP—Grant number 2016/03993-9) for providing financial support.
Author information
Authors and Affiliations
Contributions
LGAC, LALJ, HSS, FRFS, and MSC: concept and design of the review and drafted the manuscript. RR: critical revision of the manuscript. All authors significantly contributed with compilation of the literature and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
de Almeida Chuffa, L.G., Seiva, F.R.F., Cucielo, M.S. et al. Mitochondrial functions and melatonin: a tour of the reproductive cancers. Cell. Mol. Life Sci. 76, 837–863 (2019). https://doi.org/10.1007/s00018-018-2963-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-018-2963-0